Medivation Stock Doubles to Lead Prostate Cancer Biotechs | equities.com - 0 views
-
Equities Group on 04 Nov 11Stock in biotech company Medivation more than doubled in value after reports that their phase III study of a new drug to treat prostate cancer has showed major success.